Table 1 Baseline characteristics of the study subjects*
Characteristic | Ezetimibe add- on group (n = 23) | Increased rosuvastatin (n = 20) |
|---|---|---|
Age, years†| 56.5 ± 7.4 | 57.0 ± 9.9 |
Male sex | 22 (95.6) | 17 (85.0) |
Caucasian | 19 (82.6) | 15 (75.0) |
Duration of ARV therapy (months)†| 24 (16–34) | 25(14-48) |
CD4+ cell count (cells/mm3)†| 580.0 ± 193 | 508.0 ± 208 |
Undetectable VL‡ | 20 (87.0) | 19 (95.0) |
PI | 21 (91.3) | 17 (85.0) |
NNRTI | 6 (26.1) | 7 (35.0) |
NRTI | 23 (100) | 19 (95.0) |
Fibrate | 4 (17.4) | 6 (30.0) |
Antihypertensive agents | 13 (56.5) | 6 (30.0) |
Current Smoker | 6 (26.1) | 1 (5.0) |
Previous Smoker§ | 8 (34.8) | 14 (70.0) |
Diabetes Mellitus | 8 (34.8) | 7 (35.0) |
Hypertension | 13 (56.5) | 6 (30.0) |
Family History of CVD | 10 (43.5) | 10 (55.0) |
Body Mass Index (kg/m2)†| 26.0 ± 4.2 | 25.3 ± 4.7 |
Waist Circumference, cm†| 98 ± 13.7 | 93 ± 15.3 |